Johnson & Johnson announced it has completed the divestiture of its LifeScan diabetes product line to Platinum Equity for $2.1 billion.
J&J said it will continue to serve the diabetes market through its medical device, pharmaceuticals and consumer businesses.
The transaction will be discussed, J&J said, during its earning call on Oct. 16.
